Click here to get full coverage on Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX) - Seeking Alpha

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX)  Seeking Alpha

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX) - Seeking Alpha

Click here to get full coverage on Immatics (NASDAQ:IMTX) Sees Strong Trading Volume - Here's What Happened - MarketBeat

Immatics (NASDAQ:IMTX) Sees Strong Trading Volume - Here's What Happened  MarketBeat

Immatics (NASDAQ:IMTX) Sees Strong Trading Volume - Here's What Happened - MarketBeat

Click here to get full coverage on Assessing Immatics (NasdaqCM:IMTX) Valuation After Earnings Loss And Pipeline And Moderna Updates - simplywall.st

Assessing Immatics (NasdaqCM:IMTX) Valuation After Earnings Loss And Pipeline And Moderna Updates  simplywall.st

Assessing Immatics (NasdaqCM:IMTX) Valuation After Earnings Loss And Pipeline And Moderna Updates - simplywall.st

Click here to get full coverage on Cancer therapy firm Immatics funds 2028 runway despite $231M 2025 loss - Stock Titan

Cancer therapy firm Immatics funds 2028 runway despite $231M 2025 loss  Stock Titan

Cancer therapy firm Immatics funds 2028 runway despite $231M 2025 loss - Stock Titan

Click here to get full coverage on Bank of America Securities Sticks to Their Buy Rating for Immatics (IMTX) - The Globe and Mail

Bank of America Securities Sticks to Their Buy Rating for Immatics (IMTX)  The Globe and Mail

Bank of America Securities Sticks to Their Buy Rating for Immatics (IMTX) - The Globe and Mail

Click here to get full coverage on Immatics: Q4 Earnings Snapshot - KVUE

Immatics: Q4 Earnings Snapshot - KVUE

Click here to get full coverage on Jefferies Financial Group Inc. Takes $10.18 Million Position in Immatics N.V. $IMTX - MarketBeat

Jefferies Financial Group Inc. Takes $10.18 Million Position in Immatics N.V. $IMTX  MarketBeat

Jefferies Financial Group Inc. Takes $10.18 Million Position in Immatics N.V. $IMTX - MarketBeat

Click here to get full coverage on Institutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX) - Yahoo Finance

Institutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX)  Yahoo Finance

Institutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX) - Yahoo Finance

Click here to get full coverage on IMTX: Collaboration revenue dropped, R&D spending rose, and net loss widened to €196.4M in 2025 - TradingView

IMTX: Collaboration revenue dropped, R&D spending rose, and net loss widened to €196.4M in 2025  TradingView

IMTX: Collaboration revenue dropped, R&D spending rose, and net loss widened to €196.4M in 2025 - TradingView

Click here to get full coverage on (IMTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily

(IMTX) Movement as an Input in Quant Signal Sets  Stock Traders Daily

(IMTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Click here to get full coverage on Immatics (IMTX) Projects Promising Developments for 2026 After R - GuruFocus

Immatics (IMTX) Projects Promising Developments for 2026 After R  GuruFocus

Immatics (IMTX) Projects Promising Developments for 2026 After R - GuruFocus

Click here to get full coverage on Is Immatics’ 2025 Loss and PRAME Pipeline Push Altering The Investment Case For Immatics (IMTX)? - simplywall.st

Is Immatics’ 2025 Loss and PRAME Pipeline Push Altering The Investment Case For Immatics (IMTX)?  simplywall.st

Is Immatics’ 2025 Loss and PRAME Pipeline Push Altering The Investment Case For Immatics (IMTX)? - simplywall.st

Click here to get full coverage on Immatics (NASDAQ: IMTX) 2025 results show revenue drop and larger net loss - Stock Titan

Immatics (NASDAQ: IMTX) 2025 results show revenue drop and larger net loss  Stock Titan

Immatics (NASDAQ: IMTX) 2025 results show revenue drop and larger net loss - Stock Titan

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Incyte (INCY) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Incyte (INCY)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Incyte (INCY) - The Globe and Mail

Click here to get full coverage on Immatics (NASDAQ:IMTX) Shares Gap Down - Time to Sell? - MarketBeat

Immatics (NASDAQ:IMTX) Shares Gap Down - Time to Sell?  MarketBeat

Immatics (NASDAQ:IMTX) Shares Gap Down - Time to Sell? - MarketBeat

Click here to get full coverage on Immatics (NasdaqCM:IMTX) Quarterly Loss Of €50.5 Million Tests Bullish Growth Narratives - simplywall.st

Immatics (NasdaqCM:IMTX) Quarterly Loss Of €50.5 Million Tests Bullish Growth Narratives  simplywall.st

Immatics (NasdaqCM:IMTX) Quarterly Loss Of €50.5 Million Tests Bullish Growth Narratives - simplywall.st

Click here to get full coverage on Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to "Hold" - MarketBeat

Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to "Hold"  MarketBeat

Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to "Hold" - MarketBeat

Click here to get full coverage on Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28% - simplywall.st

Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28%  simplywall.st

Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28% - simplywall.st

Click here to get full coverage on Immatics (NASDAQ:IMTX) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat

Immatics (NASDAQ:IMTX) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS  MarketBeat

Immatics (NASDAQ:IMTX) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat

Click here to get full coverage on Immatics N.V. (NASDAQ:IMTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Immatics N.V. (NASDAQ:IMTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages  MarketBeat

Immatics N.V. (NASDAQ:IMTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Click here to get full coverage on Immatics Announces $125 Million Underwritten Offering - GlobeNewswire

Immatics Announces $125 Million Underwritten Offering  GlobeNewswire

Immatics Announces $125 Million Underwritten Offering - GlobeNewswire

Click here to get full coverage on Immatics (NASDAQ: IMTX) to sell 12,500,000 shares at $10.00 in underwritten offering - Stock Titan

Immatics (NASDAQ: IMTX) to sell 12,500,000 shares at $10.00 in underwritten offering  Stock Titan

Immatics (NASDAQ: IMTX) to sell 12,500,000 shares at $10.00 in underwritten offering - Stock Titan

Click here to get full coverage on Immatics: PRAME Leader's Transition To Commercial Reality - Seeking Alpha

Immatics: PRAME Leader's Transition To Commercial Reality  Seeking Alpha

Immatics: PRAME Leader's Transition To Commercial Reality - Seeking Alpha

Click here to get full coverage on IMTX Financial Assets Decline Due to R&D Spending and Exchange L - GuruFocus

IMTX Financial Assets Decline Due to R&D Spending and Exchange L  GuruFocus

IMTX Financial Assets Decline Due to R&D Spending and Exchange L - GuruFocus

Click here to get full coverage on Liquidity Mapping Around (IMTX) Price Events - Stock Traders Daily

Liquidity Mapping Around (IMTX) Price Events  Stock Traders Daily

Liquidity Mapping Around (IMTX) Price Events - Stock Traders Daily

Click here to get full coverage on Immatics (NASDAQ:IMTX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Immatics (NASDAQ:IMTX) Lowered to "Sell" Rating by Wall Street Zen  MarketBeat

Immatics (NASDAQ:IMTX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Click here to get full coverage on Immatics Earnings Report: Q4 Overview - Benzinga

Immatics Earnings Report: Q4 Overview  Benzinga

Immatics Earnings Report: Q4 Overview - Benzinga

Click here to get full coverage on Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to Hold - MarketBeat

Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to Hold  MarketBeat

Wall Street Zen Upgrades Immatics (NASDAQ:IMTX) to Hold - MarketBeat

Click here to get full coverage on Immatics (NASDAQ: IMTX) reports 46% ORR for IMA203CD8 in Phase 1a PRAME solid tumors - Stock Titan

Immatics (NASDAQ: IMTX) reports 46% ORR for IMA203CD8 in Phase 1a PRAME solid tumors  Stock Titan

Immatics (NASDAQ: IMTX) reports 46% ORR for IMA203CD8 in Phase 1a PRAME solid tumors - Stock Titan

Click here to get full coverage on Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention? - Yahoo Finance

Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention?  Yahoo Finance

Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention? - Yahoo Finance

Click here to get full coverage on What Immatics (IMTX)'s Melanoma Orphan Drug Designation Means For Shareholders - simplywall.st

What Immatics (IMTX)'s Melanoma Orphan Drug Designation Means For Shareholders  simplywall.st

What Immatics (IMTX)'s Melanoma Orphan Drug Designation Means For Shareholders - simplywall.st

Click here to get full coverage on Assessing Immatics (NasdaqCM:IMTX) Valuation After FDA Orphan Drug Designation For Its Melanoma Program - simplywall.st

Assessing Immatics (NasdaqCM:IMTX) Valuation After FDA Orphan Drug Designation For Its Melanoma Program  simplywall.st

Assessing Immatics (NasdaqCM:IMTX) Valuation After FDA Orphan Drug Designation For Its Melanoma Program - simplywall.st

Click here to get full coverage on Immatics (NASDAQ:IMTX) Shares Down 5% - Time to Sell? - MarketBeat

Immatics (NASDAQ:IMTX) Shares Down 5% - Time to Sell?  MarketBeat

Immatics (NASDAQ:IMTX) Shares Down 5% - Time to Sell? - MarketBeat

Click here to get full coverage on Evaluating Immatics (NasdaqCM:IMTX) Valuation After Recent Volatility and Sector Momentum - Yahoo Finance

Evaluating Immatics (NasdaqCM:IMTX) Valuation After Recent Volatility and Sector Momentum  Yahoo Finance

Evaluating Immatics (NasdaqCM:IMTX) Valuation After Recent Volatility and Sector Momentum - Yahoo Finance

Click here to get full coverage on Discipline and Rules-Based Execution in IMTX Response - Stock Traders Daily

Discipline and Rules-Based Execution in IMTX Response  Stock Traders Daily

Discipline and Rules-Based Execution in IMTX Response - Stock Traders Daily

Click here to get full coverage on Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering - Quiver Quantitative

Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering  Quiver Quantitative

Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering - Quiver Quantitative

Click here to get full coverage on Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX) - Yahoo Finance

Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)  Yahoo Finance

Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX) - Yahoo Finance

Click here to get full coverage on Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX) - Seeking Alpha

Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX)  Seeking Alpha

Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX) - Seeking Alpha

Click here to get full coverage on Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Announces Target Price $25 - 富途牛牛

Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Announces Target Price $25  富途牛牛

Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Announces Target Price $25 - 富途牛牛

Click here to get full coverage on Immatics 2025 collaboration revenue beats analyst expectations - TradingView

Immatics 2025 collaboration revenue beats analyst expectations  TradingView

Immatics 2025 collaboration revenue beats analyst expectations - TradingView

Click here to get full coverage on Why (IMTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Why (IMTX) Price Action Is Critical for Tactical Trading  Stock Traders Daily

Why (IMTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Click here to get full coverage on Immatics NV earnings beat by €0.13, revenue topped estimates - Investing.com Nigeria

Immatics NV earnings beat by €0.13, revenue topped estimates  Investing.com Nigeria

Immatics NV earnings beat by €0.13, revenue topped estimates - Investing.com Nigeria

Click here to get full coverage on Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps - GlobeNewswire

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps  GlobeNewswire

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps - GlobeNewswire

Click here to get full coverage on Would You Still Hold Immatics Stock If It Fell 30%? - Trefis

Would You Still Hold Immatics Stock If It Fell 30%?  Trefis

Would You Still Hold Immatics Stock If It Fell 30%? - Trefis

Click here to get full coverage on Immatics Confirms 2027 Anzu-cel Launch Timeline as PRAME Franchise and Cash Runway Advance - TipRanks

Immatics Confirms 2027 Anzu-cel Launch Timeline as PRAME Franchise and Cash Runway Advance  TipRanks

Immatics Confirms 2027 Anzu-cel Launch Timeline as PRAME Franchise and Cash Runway Advance - TipRanks

Click here to get full coverage on Immatics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st

Immatics Second Quarter 2025 Earnings: Misses Expectations  simplywall.st

Immatics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st

Click here to get full coverage on Immatics Announces Third Quarter 2025 Financial Results and Business Update - GlobeNewswire

Immatics Announces Third Quarter 2025 Financial Results and Business Update  GlobeNewswire

Immatics Announces Third Quarter 2025 Financial Results and Business Update - GlobeNewswire

Click here to get full coverage on Immatics (IMTX) Soars After Positive Trial Results for Cell Ther - GuruFocus

Immatics (IMTX) Soars After Positive Trial Results for Cell Ther  GuruFocus

Immatics (IMTX) Soars After Positive Trial Results for Cell Ther - GuruFocus

Click here to get full coverage on Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds?  Yahoo Finance

Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Click here to get full coverage on Immatics stock price target raised to $17 from $16 at Leerink Partners - Investing.com

Immatics stock price target raised to $17 from $16 at Leerink Partners  Investing.com

Immatics stock price target raised to $17 from $16 at Leerink Partners - Investing.com

Click here to get full coverage on We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth - Sahm

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth  Sahm

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth - Sahm

Click here to get full coverage on Fundamentals Check: Can IMTX expand into new markets - Quarterly Profit Review & Growth Focused Entry Point Reports - baoquankhu1.vn

Fundamentals Check: Can IMTX expand into new markets - Quarterly Profit Review & Growth Focused Entry Point Reports  baoquankhu1.vn

Fundamentals Check: Can IMTX expand into new markets - Quarterly Profit Review & Growth Focused Entry Point Reports - baoquankhu1.vn

Click here to get full coverage on Immatics Reveals Promising Phase 1a Results for TCR Bispecifics - TipRanks

Immatics Reveals Promising Phase 1a Results for TCR Bispecifics  TipRanks

Immatics Reveals Promising Phase 1a Results for TCR Bispecifics - TipRanks

Click here to get full coverage on Immatics NV earnings beat by €0.13, revenue topped estimates - Investing.com South Africa

Immatics NV earnings beat by €0.13, revenue topped estimates  Investing.com South Africa

Immatics NV earnings beat by €0.13, revenue topped estimates - Investing.com South Africa

Click here to get full coverage on Earnings Flash (IMTX) Immatics Posts Q2 Net Loss 0.58 Euros a Share, vs. FactSet Est of 0.28 Euros Loss - marketscreener.com

Earnings Flash (IMTX) Immatics Posts Q2 Net Loss 0.58 Euros a Share, vs. FactSet Est of 0.28 Euros Loss  marketscreener.com

Earnings Flash (IMTX) Immatics Posts Q2 Net Loss 0.58 Euros a Share, vs. FactSet Est of 0.28 Euros Loss - marketscreener.com

Click here to get full coverage on Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances - Stock Titan

Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances  Stock Titan

Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances - Stock Titan

Click here to get full coverage on Immatics Publishes Updated PRAME-Focused Investor Presentation on January 12, 2026 - TipRanks

Immatics Publishes Updated PRAME-Focused Investor Presentation on January 12, 2026  TipRanks

Immatics Publishes Updated PRAME-Focused Investor Presentation on January 12, 2026 - TipRanks

Click here to get full coverage on Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead (NASDAQ:IOVA) - Seeking Alpha

Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead (NASDAQ:IOVA)  Seeking Alpha

Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead (NASDAQ:IOVA) - Seeking Alpha

Click here to get full coverage on Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire

Immatics Announces Full Year 2024 Financial Results and Business Update  GlobeNewswire

Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire

Click here to get full coverage on Why Is Immatics N.V. (IMTX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Yahoo Finance

Why Is Immatics N.V. (IMTX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?  Yahoo Finance

Why Is Immatics N.V. (IMTX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Yahoo Finance

Click here to get full coverage on Immatics: A Promising TCR Pipeline (NASDAQ:IMTX) - Seeking Alpha

Immatics: A Promising TCR Pipeline (NASDAQ:IMTX)  Seeking Alpha

Immatics: A Promising TCR Pipeline (NASDAQ:IMTX) - Seeking Alpha

Click here to get full coverage on Immatics Stock: Big Pharma Partners, Intriguing Catalysts Make Buy Case (NASDAQ:IMTX) - Seeking Alpha

Immatics Stock: Big Pharma Partners, Intriguing Catalysts Make Buy Case (NASDAQ:IMTX)  Seeking Alpha

Immatics Stock: Big Pharma Partners, Intriguing Catalysts Make Buy Case (NASDAQ:IMTX) - Seeking Alpha

Click here to get full coverage on Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns - Yahoo Finance

Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns  Yahoo Finance

Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns - Yahoo Finance

Click here to get full coverage on Immatics Faces Termination of Key Collaboration with Bristol Myers Squibb - Nasdaq

Immatics Faces Termination of Key Collaboration with Bristol Myers Squibb  Nasdaq

Immatics Faces Termination of Key Collaboration with Bristol Myers Squibb - Nasdaq

Click here to get full coverage on Immatics Announces Pricing of $150 Million Public Offering - GlobeNewswire

Immatics Announces Pricing of $150 Million Public Offering  GlobeNewswire

Immatics Announces Pricing of $150 Million Public Offering - GlobeNewswire

Click here to get full coverage on Immatics Announces Proposed $150 Million Public Offering - GlobeNewswire

Immatics Announces Proposed $150 Million Public Offering  GlobeNewswire

Immatics Announces Proposed $150 Million Public Offering - GlobeNewswire

Click here to get full coverage on Here's Why We Think Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Looks Fair for the Time Being - 富途牛牛

Here's Why We Think Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Looks Fair for the Time Being  富途牛牛

Here's Why We Think Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Looks Fair for the Time Being - 富途牛牛

Click here to get full coverage on dievini Hopp BioTech holding GmbH & Co KG Updates Holdings in Immatics (IMTX) - Nasdaq

dievini Hopp BioTech holding GmbH & Co KG Updates Holdings in Immatics (IMTX)  Nasdaq

IMTX

Price Chart

Key Statistics

Technicals

About IMTX

Latest News

Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX) - Seeking Alpha

Immatics (NASDAQ:IMTX) Sees Strong Trading Volume - Here's What Happened - MarketBeat

Assessing Immatics (NasdaqCM:IMTX) Valuation After Earnings Loss And Pipeline And Moderna Updates - simplywall.st

Advanced Charts

Top Gainers

Top Losers